Drug Profile

Abemaciclib - Eli Lilly and Company

Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; LY 2835219; Verzenio; Verzenios

Latest Information Update: 27 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eli Lilly and Company
Developer Boehringer Ingelheim; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Jules Bordet Institute; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; UCLAs Jonsson Comprehensive Cancer Center; Washington University School of Medicine
Class Aminopyridines; Antineoplastics; Benzimidazoles; Fluorinated hydrocarbons; Piperazines; Pyrimidines; Small molecules
Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Marketed Breast cancer
Phase III HER2 negative breast cancer; Liposarcoma; Prostate cancer
Phase II Adenocarcinoma; Brain cancer; Cholangiocarcinoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Glioblastoma; Mantle-cell lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Urogenital cancer
Phase I/II Head and neck cancer
Phase I Myelofibrosis
No development reported Cancer; Renal cell carcinoma

28 Jan 2025 Sermonix Pharmaceuticals and Eli Lilly and Company completes the phase II ELAINE 2 trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04432454)
26 Dec 2024 Eli Lilly completes an expanded-access programme for Breast Cancer (Late-stage disease) in Australia, Canada, Egypt, India, Italy, Malaysia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, United Kingdom (NCT03763604)
29 Oct 2024 Eli Lilly Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully completes the negotiations for Verzenio's expanded indication in Breast cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com